AN2 Therapeutics
ANTX
66 hedge funds and large institutions have $119M invested in AN2 Therapeutics in 2026 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 14 closing their positions.
100% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 14
59% more capital invested
Capital invested by funds: $74.8M → $119M (+$44.2M)
27% more funds holding
Funds holding: 52 → 66 (+14)
7.34% more ownership
Funds ownership: 60.92% → 68.26% (+7.3%)
7% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.79M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$3.43M |
| 3 |
CC
Commodore Capital
New York
|
+$2.58M |
| 4 |
SC
SummitTX Capital
Fort Worth,
Texas
|
+$2.57M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$2.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$2.3M |
| 2 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
-$1.57M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1.07M |
| 4 |
Jane Street
New York
|
-$1.04M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$890K |
ANTX Hedge Fund Activity: Q2 2026 in Review
66 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q2 2026, worth a combined $119M — up 59% from $74.8M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ANTX positions and 14 closed out — a net gain of 14 holders — while 15 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $5.79M. The largest seller was Woodline Partners, cutting an estimated $2.3M.
- 66 institutional investors held AN2 Therapeutics (ANTX) as of Q2 2026, up from 52 in Q1 2026.
- Funds reported $119M of AN2 Therapeutics stock for Q2 2026, up 59% quarter-over-quarter.
- 28 funds opened new AN2 Therapeutics positions in Q2 2026 and 14 closed out, a net change of +14 holders.
- The largest AN2 Therapeutics buyer in Q2 2026 was BlackRock, an estimated $5.79M added.
- The largest AN2 Therapeutics seller in Q2 2026 was Woodline Partners, an estimated $2.3M sold.
Based on aggregated 13F filings for Q2 2026.